Medical Condition News

RSS

FDA approves expanded indication for Boston Scientific's CRT-Ds

Boston Scientific Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for its cardiac resynchronization therapy defibrillators (CRT-Ds), including the COGNIS® CRT-D. The exclusive expanded indication is effective immediately and makes Boston Scientific CRT-Ds the only devices approved by the FDA for patients in all New York Heart Association (NYHA) classes of heart failure.

17 Sep 2010

Metabolism imbalance increases asthma risk in children: Research

Even children of a healthy weight who have an imbalanced metabolism due to poor diet or exercise may be at increased risk of asthma, according to new research, which challenges the widespread assumption that obesity itself is a risk factor for asthma.

17 Sep 2010

FDA Advisory Committee recommends approval of Alkermes' VIVITROL for opioid dependence

Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted 12 to 1 that VIVITROL® (naltrexone for extended-release injectable suspension) should be approved for the treatment of opioid dependence.

17 Sep 2010

Medtronic Deep Brain Stimulation Therapy for severe epilepsy receives CE Mark approval

Medtronic, Inc. today announced that the company has received CE (Conformité Européenne) Mark approval for Medtronic Deep Brain Stimulation (DBS) Therapy in Europe as adjunctive treatment for partial-onset seizures in adults with medically refractory epilepsy. DBS therapy for epilepsy delivers controlled electrical pulses to a target in the brain called the anterior nucleus of the thalamus, which is part of a circuit involved in seizures.

17 Sep 2010

FDA approves CRT-D device to treat heart failure patients

The U.S. Food and Drug Administration today approved a new indication for three cardiac resynchronization therapy defibrillators (CRT-D) used to treat certain heart failure patients.

17 Sep 2010

FDA grants AGTC $1M for Phase II human clinical trial in alpha-1 antitrypsin deficiency

Applied Genetic Technologies Corporation, a privately-held, clinical stage biotechnology company developing novel systems to deliver human therapeutics, announces that it has received a grant of $1 million from the Food and Drug Administration (FDA Orphan Drugs Program) to fund a Phase II Human Clinical Trial evaluating the safety and efficacy of a treatment for Alpha 1 Antitrypsin Deficiency (AAT), a genetic disease known to result in serious lung and/or liver disease.

17 Sep 2010

Researchers identify bacteria responsible for chronic intestinal inflammation

Certain bacteria that inhabit the intestine provide the environmental trigger that initiates and perpetuates chronic intestinal inflammation in individuals who are genetically susceptible to inflammatory bowel disease (IBD), a study led by Harvard School of Public Health researchers has found.

17 Sep 2010

Scientists discover protein to regulate blood stem cells’ activity for leukemia treatment

A discovery made by Dr. Tarik Möröy, President and Scientific Director and Director of the IRCM, and his team was recently published in Blood, the official journal of the American Society of Hematology. The researchers found that a protein can regulate certain characteristics of blood stem cells, which could lead to a better treatment for leukemia patients.

17 Sep 2010

Solta Medical's Fraxel re:store Dual system for actinic keratosis receives FDA 510(k) clearance

Solta Medical, Inc., the pioneer in fractional resurfacing and non-invasive skin tightening and a market leader in aesthetic skin treatments, today announced it has received FDA 510(k) clearance of its Fraxel re:store®Dual for the treatment of actinic keratosis (AKs). The Fraxel re:store Dual system takes the industry leading fractional laser technology to the next level by adding a novel 1927 nm wavelength, the first ever application of a Thulium laser in the aesthetics market.

17 Sep 2010

Artificial pancreas for diabetics

In another few years diabetics may be treated using an artificial pancreas developed by Professor Joan Taylor professor of Pharmaceutics at De Montfort University (DMU), Leicester. This could mean freedom from daily insulin injections she said.

16 Sep 2010

Severe acne linked to suicidal thoughts in teenagers

According to a new study on Norwegian youth, compared to clear-skinned peers, teens who have bad acne are more than twice as likely to have mental health problems and are at greater risk of having suicidal thoughts.

16 Sep 2010

ISTA Pharmaceuticals initiates REMURA Phase 3 clinical program for dry eye disease

ISTA Pharmaceuticals, Inc., today announced that it has initiated a Phase 3 clinical program of ISTA's proprietary formulation of REMURA (bromfenac ophthalmic solution for dry eye) for alleviating the signs and symptoms of dry eye disease. The Phase 3 efficacy studies are being conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. Food and Drug Administration (FDA).

16 Sep 2010

CDPAC to work with health ministers on concrete actions to address childhood obesity

The Chronic Disease Prevention Alliance of Canada (CDPAC), a coalition comprised of ten national organizations committed to integrated action for chronic disease prevention in Canada, commends the federal, provincial and territorial ministers of health for their commitment to address the issue of childhood obesity at their meeting in St. John's Newfoundland yesterday.

16 Sep 2010

HFSA to discuss 'Designing the Medical Home for Heart Failure Patients' at Scientific Meeting

The 14th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) will feature a discussion titled "Designing the Medical Home for Heart Failure Patients." Contributors Dr. Mary Norine Walsh and Dr. Larry A. Allen will describe treatment and care strategies in the medical home model and how they impact both patients and caregivers.

16 Sep 2010

Alzheimer Society, Coffee Break commits to support Canadians living with Alzheimer's disease

Today, hundreds of people across the nation have made the commitment to make their "coffee count" and are drinking a cup of coffee to raise funds in support of Canadians living with Alzheimer's disease or a related dementia. This marks 15 years' of successful grassroots fundraising by the Alzheimer Society, raising over $12 million in support of essential programs and services for people with dementia, their families and caregivers.

16 Sep 2010

Retina Implant AG presents clinical data of successful subretinal electronic implants

Retina Implant AG, a leading developer of subretinal implants for the visually impaired, today announced the presentation of findings obtained during their first human clinical trial in the form of two oral presentations at The Eye and the Chip 2010 Annual Meeting in Detroit, Mich.

16 Sep 2010

Intensive care diary entries can reduce PTSD rates: Study

Some intensive care patients develop post-traumatic stress syndrome (PTSD) after the trauma of a difficult hospital stay, and this is thought to be exacerbated by delusional or fragmentary memories of their time in the intensive care unit. Now researchers writing in BioMed Central's open access journal Critical Care have found that if staff and close relatives make a diary for patients, featuring information about their stay and accompanied by photographs, PTSD rates can be significantly reduced.

16 Sep 2010

BioCryst Pharmaceuticals announces BCX4208 compound results for treating gout

BioCryst Pharmaceuticals, Inc. announced positive top-line results from its randomized, double-blind, multi-center, placebo-controlled Phase 2 study designed to evaluate the urate-lowering activity and safety of several doses of BCX4208 alone and in combination with selected doses of allopurinol administered once-daily.

16 Sep 2010

Hormone Foundation produces two fact sheets to dispel myths of adrenal fatigue, Wilson's temperature syndrome

The Hormone Foundation, the public education affiliate of The Endocrine Society, has produced two new fact sheets to dispel myths about so-called "diseases" popularized through the Internet: adrenal fatigue and Wilson's temperature syndrome.

16 Sep 2010

NHLBI selects NuGEN to provide automated reagent solutions for expression profiling

NuGEN Technologies, the provider of innovative RNA and DNA amplification and sample preparation technologies for genomic analysis, today announced it has been selected by the National Heart, Lung, and Blood Institute (NHLBI) to provide automated reagent solutions for expression profiling of approximately 6,000 blood samples from the Framingham Heart Study.

16 Sep 2010

Medical Condition News

FDA approves expanded indication for Boston Scientific's CRT-Ds

Metabolism imbalance increases asthma risk in children: Research

FDA Advisory Committee recommends approval of Alkermes' VIVITROL for opioid dependence

Medtronic Deep Brain Stimulation Therapy for severe epilepsy receives CE Mark approval

FDA approves CRT-D device to treat heart failure patients

FDA grants AGTC $1M for Phase II human clinical trial in alpha-1 antitrypsin deficiency

Researchers identify bacteria responsible for chronic intestinal inflammation

Scientists discover protein to regulate blood stem cells’ activity for leukemia treatment

Solta Medical's Fraxel re:store Dual system for actinic keratosis receives FDA 510(k) clearance

Artificial pancreas for diabetics

Severe acne linked to suicidal thoughts in teenagers

ISTA Pharmaceuticals initiates REMURA Phase 3 clinical program for dry eye disease

CDPAC to work with health ministers on concrete actions to address childhood obesity

HFSA to discuss 'Designing the Medical Home for Heart Failure Patients' at Scientific Meeting

Alzheimer Society, Coffee Break commits to support Canadians living with Alzheimer's disease

Retina Implant AG presents clinical data of successful subretinal electronic implants

Intensive care diary entries can reduce PTSD rates: Study

BioCryst Pharmaceuticals announces BCX4208 compound results for treating gout

Hormone Foundation produces two fact sheets to dispel myths of adrenal fatigue, Wilson's temperature syndrome

NHLBI selects NuGEN to provide automated reagent solutions for expression profiling

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News